Back to search results
NCT07472023

Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss

Enrolling by Invitation
EARLY_PHASE1All AgesInterventionalTreatment
Truway Health, Inc.
~120 participants
Updated 2026-03-16 on ClinicalTrials.gov
What's tested:Audiologic MonitoringInvestigational Regenerative Pharmacologic TherapyStem Cell Regenerative TherapyCombination Regenerative Therapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Pure-Tone Audiometry Hearing Threshold (dB HL)
Measured over Baseline to 6 months

Conditions

Sensorineural Hearing Loss
Tinnitus
Acoustic Trauma
Inner Ear Injury
Noise-Induced Hearing Loss
Sudden Hearing Loss
Vestibular Dysfunction

Explore related trials

Injury of Inner EarSensorineural Hearing LossTinnitus

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Gavin C Solomon, CEO · PRINCIPAL_INVESTIGATOR · Truway Health, Inc.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Change in Pure-Tone Audiometry Hearing Threshold (dB HL)Baseline to 6 months

    Change in hearing threshold levels measured in decibels hearing level (dB HL) across standard audiometric frequencies (0.25-8 kHz) using calibrated pure-tone audiometry. Lower dB HL values indicate improved auditory sensitivity.